List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/42368/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Rivastigmine for Dementia Associated with Parkinson's Disease. New England Journal of Medicine, 2004, 351, 2509-2518.	27.0	1,111
2	Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial. Lancet Neurology, The, 2013, 12, 37-44.	10.2	607
3	Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease. New England Journal of Medicine, 2019, 380, 315-324.	27.0	225
4	Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2018, 17, 749-759.	10.2	203
5	Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations. Brain, 2009, 132, 2980-2993.	7.6	163
6	Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease – Clinical practice recommendations. Parkinsonism and Related Disorders, 2015, 21, 1023-1030.	2.2	126
7	Environmental exposure to pesticides and the risk of Parkinson's disease in the Netherlands. Environment International, 2017, 107, 100-110.	10.0	121
8	Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. Movement Disorders, 2001, 16, 197-201.	3.9	111
9	Peripheral neuropathy in Parkinson's disease: Levodopa exposure and implications for duodenal delivery. Parkinsonism and Related Disorders, 2013, 19, 501-507.	2.2	99
10	Retinal layers in Parkinson's disease: A meta-analysis of spectral-domain optical coherence tomography studies. Parkinsonism and Related Disorders, 2019, 64, 40-49.	2.2	91
11	Postoperative gait deterioration after bilateral subthalamic nucleus stimulation in Parkinson's disease. Movement Disorders, 2008, 23, 2404-2406.	3.9	87
12	Adaptive DBS in a Parkinson's patient with chronically implanted DBS: A proof of principle. Movement Disorders, 2017, 32, 1253-1254.	3.9	73
13	FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder. Movement Disorders, 2017, 32, 1482-1486.	3.9	67
14	Pharmacokinetic-Pharmacodynamic Relationships of Apomorphine in Patients with Parkinson??s Disease. Clinical Pharmacokinetics, 1999, 37, 257-271.	3.5	66
15	Visual object recognition and attention in Parkinson's disease patients with visual hallucinations. Movement Disorders, 2008, 23, 1906-1912.	3.9	66
16	Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients. Parkinsonism and Related Disorders, 2016, 23, 17-22.	2.2	63
17	Long-term Safety of Rivastigmine in Parkinson Disease Dementia. Clinical Neuropharmacology, 2014, 37, 9-16.	0.7	62
18	Effects of Cholinesterase Inhibitors in Parkinson's Disease Dementia: A Review of Clinical Data. CNS Neuroscience and Therapeutics, 2011, 17, 428-441.	3.9	61

#	Article	IF	CITATIONS
19	Abnormal pattern of brain glucose metabolism in Parkinson's disease: replication in three European cohorts. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 437-450.	6.4	54
20	Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease. Pharmaceutical Research, 1997, 14, 1804-1810.	3.5	52
21	A Case-Control Study of the Protective Effect of Alcohol, Coffee, and Cigarette Consumption on Parkinson Disease Risk: Time-Since-Cessation Modifies the Effect of Tobacco Smoking. PLoS ONE, 2014, 9, e95297.	2.5	52
22	Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonism. Movement Disorders, 2007, 22, 2430-2435.	3.9	50
23	Attentional and perceptual impairments in Parkinson's disease with visual hallucinations. Parkinsonism and Related Disorders, 2010, 16, 270-274.	2.2	48
24	Regional cortical grey matter loss in Parkinson's disease without dementia is independent from visual hallucinations. Movement Disorders, 2011, 26, 142-147.	3.9	48
25	Effective Delivery of Apomorphine in the Management of Parkinson Disease. Clinical Neuropharmacology, 2015, 38, 89-103.	0.7	48
26	Functional (psychogenic) movement disorders associated with normal scores in psychological questionnaires: A case control study. Journal of Psychosomatic Research, 2015, 79, 190-194.	2.6	46
27	Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations. Parkinsonism and Related Disorders, 2010, 16, 71-72.	2.2	42
28	A <scp>Largeâ€Scale</scp> Full <scp><i>GBA1</i></scp> Gene Screening in Parkinson's Disease in the Netherlands. Movement Disorders, 2020, 35, 1667-1674.	3.9	41
29	Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease. Movement Disorders, 2021, 36, 642-650.	3.9	41
30	Parkinson's disease, visual hallucinations and apomorphine: A review of the available evidence. Parkinsonism and Related Disorders, 2016, 27, 35-40.	2.2	40
31	A Guideline for Parkinson's Disease Nurse Specialists, with Recommendations for Clinical Practice. Journal of Parkinson's Disease, 2017, 7, 749-754.	2.8	39
32	Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. Parkinsonism and Related Disorders, 2021, 83, 79-85.	2.2	39
33	Deep Brain Stimulation for Essential Tremor: A Comparison of Targets. World Neurosurgery, 2018, 110, e580-e584.	1.3	38
34	Levodopa-Induced Response Fluctuations in Patients with Parkinson???s Disease. CNS Drugs, 2003, 17, 475-489.	5.9	36
35	Cognitive and psychiatric outcome 3 years after globus pallidus pars interna or subthalamic nucleus deep brain stimulation for Parkinson's disease. Parkinsonism and Related Disorders, 2016, 33, 90-95.	2.2	36
36	Clinical Relevance of Pharmacological and Physiological Data in Intrathecal Baclofen Therapy. Archives of Physical Medicine and Rehabilitation, 2014, 95, 2199-2206.	0.9	34

#	Article	IF	CITATIONS
37	Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study. Parkinsonism and Related Disorders, 2017, 45, 33-38.	2.2	34
38	Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. Movement Disorders, 2008, 23, 1532-1540.	3.9	33
39	Understanding the role of the Parkinson's disease nurse specialist in the delivery of apomorphine therapy. Parkinsonism and Related Disorders, 2016, 33, S49-S55.	2.2	31
40	SCOPA ognition cutoff value for detection of Parkinson's disease dementia. Movement Disorders, 2011, 26, 1881-1886.	3.9	30
41	Occupational exposure to pesticides and endotoxin and Parkinson disease in the Netherlands. Occupational and Environmental Medicine, 2014, 71, 757-764.	2.8	29
42	Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease. Movement Disorders, 2011, 26, 331-334.	3.9	27
43	Altered Cholinergic Innervation in De Novo Parkinson's Disease with and Without Cognitive Impairment. Movement Disorders, 2022, 37, 713-723.	3.9	27
44	Mental slowness in patients with Parkinson's disease: Associations with cognitive functions?. Journal of Clinical and Experimental Neuropsychology, 2016, 38, 844-852.	1.3	26
45	Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease. CNS Neuroscience and Therapeutics, 2010, 16, 246-253.	3.9	25
46	Improved Gait Performance in a Patient With Hereditary Spastic Paraplegia After a Continuous Intrathecal Baclofen Test Infusion and Subsequent Pump Implantation: A Case Report. Archives of Physical Medicine and Rehabilitation, 2015, 96, 1166-1169.	0.9	23
47	Characteristics of dystonia in the 18p deletion syndrome, including a new case. Clinical Neurology and Neurosurgery, 2009, 111, 880-882.	1.4	22
48	Graphical Tasks to Measure Upper Limb Function in Patients With Parkinson's Disease: Validity and Response to Dopaminergic Medication. IEEE Journal of Biomedical and Health Informatics, 2017, 21, 283-289.	6.3	21
49	Antiparkinsonian drugs causing inappropriate antidiuretic hormone secretion. Movement Disorders, 1998, 13, 176-178.	3.9	20
50	Occupational exposure to solvents, metals and welding fumes and risk of Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 635-639.	2.2	20
51	Objective Versus Subjective Measures of Executive Functions: Predictors of Participation and Quality of Life in Parkinson Disease?. Archives of Physical Medicine and Rehabilitation, 2017, 98, 2181-2187.	0.9	20
52	[ <sup>18</sup> F]Fluoroethoxybenzovesamicol in Parkinson's disease patients: Quantification of a novel cholinergic positron emission tomography tracer. Movement Disorders, 2019, 34, 924-926.	3.9	20
53	The role of EDTA in provoking allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease: A histologic study. Movement Disorders, 1998, 13, 52-55.	3.9	19
54	The Effects of Apomorphine on Visual Perception in Patients With Parkinson Disease and Visual Hallucinations. Clinical Neuropharmacology, 2009, 32, 266-268.	0.7	19

#	Article	IF	CITATIONS
55	The treatment of early Parkinson's disease: levodopa rehabilitated. Practical Neurology, 2011, 11, 145-152.	1.1	19
56	Unmet needs in Parkinson's disease: New horizons in a changing landscape. Parkinsonism and Related Disorders, 2016, 33, S2-S8.	2.2	19
57	Accuracy of Intraoperative Computed Tomography in Deep Brain Stimulation—A Prospective Noninferiority Study. Neuromodulation, 2019, 22, 472-477.	0.8	18
58	Multicenter Validation of Metabolic Abnormalities Related to <scp>PSP</scp> According to the <scp>MDSâ€PSP</scp> Criteria. Movement Disorders, 2020, 35, 2009-2018.	3.9	18
59	The role and structure of the multidisciplinary team in the management of advanced Parkinson's disease with a focus on the use of levodopa–carbidopa intestinal gel. Journal of Multidisciplinary Healthcare, 2017, Volume 10, 13-27.	2.7	17
60	Study protocol of the DUtch PARkinson Cohort (DUPARC): a prospective, observational study of de novo Parkinson's disease patients for the identification and validation of biomarkers for Parkinson's disease subtypes, progression and pathophysiology. BMC Neurology, 2020, 20, 245.	1.8	17
61	Electrical stimulation of the nucleus basalis of meynert: a systematic review of preclinical and clinical data. Scientific Reports, 2021, 11, 11751.	3.3	17
62	Lasting visual hallucinations in visual deprivation; fMRI correlates and the influence of rTMS. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1295-1296.	1.9	16
63	Quick Titration of Pergolide in Cotreatment with Domperidone Is Safe and Effective. Clinical Neuropharmacology, 2001, 24, 177-180.	0.7	15
64	Cerebral topography of vesicular cholinergic transporter changes in neurologically intact adults: A [18F]FEOBV PET study. Aging Brain, 2022, 2, 100039.	1.3	15
65	Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson's disease: the LEAP-study. BMC Neurology, 2015, 15, 236.	1.8	14
66	Cutaneous adverse drug reaction after apomorphine infusion, possibly caused by a systemic type IV hypersensitivity reaction to sodium metabisulfite: Report of 2 cases. Contact Dermatitis, 2018, 79, 316-318.	1.4	13
67	Extremely low-frequency magnetic field exposure, electrical shocks and risk of Parkinson's disease. International Archives of Occupational and Environmental Health, 2015, 88, 227-234.	2.3	12
68	Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease. Journal of Parkinson's Disease, 2018, 8, 71-84.	2.8	12
69	Pre-Movement Cortico-Muscular Dynamics Underlying Improved Parkinson Gait Initiation after Instructed Arm Swing. Journal of Parkinson's Disease, 2020, 10, 1675-1693.	2.8	12
70	Oscillatory activity and cortical coherence of the nucleus basalis of Meynert in Parkinson's disease dementia. Parkinsonism and Related Disorders, 2018, 52, 102-106.	2.2	11
71	Effect of Pharmacist-Led Interventions on (Non)Motor Symptoms, Medication-Related Problems, and Quality of Life in Parkinson Disease Patients: A Pilot Study. Clinical Neuropharmacology, 2018, 41, 14-19.	0.7	11
72	Effectiveness of ReSET; a strategic executive treatment for executive dysfunctioning in patients with Parkinson's disease. Neuropsychological Rehabilitation, 2020, 30, 67-84.	1.6	11

#	Article	IF	CITATIONS
73	How Many Patients would Benefit from Steering Technology for Deep Brain Stimulation?. Brain Stimulation, 2016, 9, 144-145.	1.6	10
74	Optimal Parameters of Deep Brain Stimulation in Essential Tremor: A Meta-Analysis and Novel Programming Strategy. Journal of Clinical Medicine, 2020, 9, 1855.	2.4	10
75	The need for non-oral therapy in Parkinson's disease; a potential role for apomorphine. Parkinsonism and Related Disorders, 2016, 33, S22-S27.	2.2	9
76	The Intraoperative Microlesion Effect Positively Correlates With the Short-Term Clinical Effect of Deep Brain Stimulation in Parkinson's Disease. Neuromodulation, 2023, 26, 459-465.	0.8	9
77	Enhanced arm swing improves Parkinsonian gait with EEG power modulations resembling healthy gait. Parkinsonism and Related Disorders, 2021, 91, 96-101.	2.2	9
78	Population Pharmacokinetics of Apomorphine in Patients with Parkinson's Disease. Drug Investigation, 1994, 7, 183-190.	0.6	8
79	Fallacious falls. Journal of Neurology, 2005, 252, 1271-1273.	3.6	8
80	Predictors of Time to Discontinuation of Levodopa-Carbidopa Intestinal Gel Infusion: A Retrospective Cohort Study. Journal of Parkinson's Disease, 2020, 10, 935-944.	2.8	8
81	Long-Term Patient-Reported Outcome of Radiofrequency Thalamotomy for Tremor. Stereotactic and Functional Neurosurgery, 2020, 98, 187-192.	1.5	8
82	Self-Reported Visual Complaints in People with Parkinson's Disease: A Systematic Review. Journal of Parkinson's Disease, 2022, 12, 785-806.	2.8	8
83	Cholinergic systems, attentional-motor integration, and cognitive control in Parkinson's disease. Progress in Brain Research, 2022, 269, 345-371.	1.4	8
84	Intraoperative Quantification of MDS-UPDRS Tremor Measurements Using 3D Accelerometry: A Pilot Study. Journal of Clinical Medicine, 2022, 11, 2275.	2.4	8
85	Establishing apomorphine treatment in Thailand: understanding the challenges and opportunities of Parkinson's disease management in developing countries. Expert Review of Neurotherapeutics, 2020, 20, 523-537.	2.8	7
86	The added value of semimicroelectrode recording in deep brain stimulation of the subthalamic nucleus for Parkinson disease. Neurosurgical Focus, 2013, 35, E3.	2.3	6
87	rTMS treatment of visual hallucinations using a connectivity-based targeting method - A case study. Brain Stimulation, 2019, 12, 1622-1624.	1.6	6
88	Early Factors for Predicting Discontinuation to Subcutaneous Apomorphine Infusion in Parkinson's disease: A Prospective Analysis of the Thai Apomorphine Registry. Parkinsonism and Related Disorders, 2021, 91, 146-151.	2.2	6
89	Systematic analysis of PINK1 variants of unknown significance shows intact mitophagy function for most variants. Npj Parkinson's Disease, 2021, 7, 113.	5.3	6
90	Postural and gait symptoms in de novo Parkinson's disease patients correlate with cholinergic white matter pathology. Parkinsonism and Related Disorders, 2021, 93, 43-49.	2.2	6

#	Article	IF	CITATIONS
91	Lateral and Medial Ventral Occipitotemporal Regions Interact During the Recognition of Images Revealed from Noise. Frontiers in Human Neuroscience, 2015, 9, 678.	2.0	5
92	Successful treatment of intractable visual hallucinations with 5-HT2Aantagonist ketanserin. BMJ Case Reports, 2018, 2018, bcr-2018-224340.	0.5	4
93	Comparison of two software programs to be used for the calculation of population pharmacokinetic parameters. International Journal of Bio-medical Computing, 1994, 36, 143-150.	0.5	3
94	Letter to the editor, "Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medicationsâ€: Parkinsonism and Related Disorders, 2022, 97, 99-100.	2.2	3
95	Substituting the Target After Unsatisfactory Outcome of Deep Brain Stimulation in Advanced Parkinson's Disease: Cases From the NSTAPS Trial and Systematic Review of the Literature. Neuromodulation, 2018, 21, 527-531.	0.8	2
96	Introduction: The Gut-Brain Axis in Parkinson's Disease. Journal of Parkinson's Disease, 2019, 9, S279-S279.	2.8	2
97	Treatment of subcutaneous nodules after infusion of apomorphine; a biopsy-controlled study comparing 4 frequently used therapies. Parkinsonism and Related Disorders, 2021, 89, 38-40.	2.2	1
98	Serendipitous Stimulation of Nucleus Basalis of Meynert—The Effect of Unintentional, Long-Term High-Frequency Stimulation on Cognition in Parkinson's Disease. Journal of Clinical Medicine, 2022, 11, 337.	2.4	1
99	1.IS.3. On-going developments in the use of apomorphine in complex Parkinson's disease (Britannia) Tj ETQq1 1	0.784314 2.2	rgBT /Over
100	Continuous Drug Delivery with Levodopa/Carbidopa Infusion: <i>Review and First Data of a Dutch Cohort</i> . CNS Spectrums, 2008, 13, 11-14.	1.2	0
101	Deep Brain Stimulation in a Dopaminergic Non-responsive Patient With Parkinson's Disease: Case Report and Systematic Review. Brain Stimulation, 2015, 8, 983-985.	1.6	0
102	Effect of pharmacist-led interventions on motor symptoms in Parkinson's patients: A pilot study. Parkinsonism and Related Disorders, 2016, 22, e27-e28.	2.2	0
103	Effect of pharmacist-led interventions on motor symptoms in Parkinson's patients: A pilot study. Parkinsonism and Related Disorders, 2016, 22, e87-e88.	2.2	0
104	Diepe hersenstimulatie bij de ziekte van Parkinson. , 2016, , 77-83.		0

Diepe hersenstimulatie bij de ziekte van Parkinson. , 2016, , 77-83. 104